PomDoctor Files for Nasdaq IPO to Expand Chronic Disease Management Services
Guangzhou-based PomDoctor Limited, a leading online medical services platform for chronic disease management, has filed...
Rona Therapeutics Initiates Phase II Study for RN0361 in Severe Hypertriglyceridemia
Shanghai-based Rona Therapeutics Inc. announced receiving approval from the US Food and Drug Administration (FDA)...
Hengrui Pharmaceuticals Receives NMPA Clearance for HRS-6213 in Solid Tumor Diagnosis
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving clearance from the National Medical...
Alphamab Oncology’s JSKN033 Receives Breakthrough Therapy Designation for Platinum Resistant Ovarian Cancer
China-based Alphamab Oncology (HKG: 9966) announced receiving Breakthrough Therapy Designation (BTD) from the National Medical...
AstraZeneca to Acquire EsoBiotec for Up to $1 Billion to Boost Cell Therapy Portfolio
On March 17, 2025, EsoBiotec SA announced a definitive acquisition agreement with AstraZeneca (NASDAQ: AZN)....
AstraZeneca Licenses Alteogen’s ALT-B4 for Subcutaneous Cancer Therapies
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) has entered into a licensing agreement with South Korea-headquartered...
Merck & Co.’s Winrevair Approved for Pulmonary Arterial Hypertension in Hainan
US-based giant Merck & Co., Inc. (NYSE: MRK) announced receiving approval from the Hainan Medical...
Visirna Therapeutics Announces Positive Phase III Results for Plozasiran in FCS Treatment
Shanghai-based Visirna Therapeutics announced positive topline results from the Phase III study of plozasiran in...
ROBO Medical’s Innovative Gastrointestinal Endoscopic Instrument Gains NMPA Approval
China’s National Medical Products Administration (NMPA) has approved ROBO Medical’s gastrointestinal endoscopic surgical instrument control...
Basilea Pharmaceutica Marks Milestone as Cresemba Sales Soar in Asia Pacific
Switzerland-based Basilea Pharmaceutica Ltd (SWX: BSLN) announced that its antifungal Cresemba (isavuconazole), commercialized by Pfizer...
Phenomenex Inaugurates China R&D Center to Advance Danaher’s “Launching China” Strategy
California-based Phenomenex, a leading manufacturer of chromatography consumables, announced the inauguration of its R&D center...
BMS’s Breyanzi Approved by EC for Relapsed or Refractory Follicular Lymphoma
US giant Bristol-Myers Squibb (BMS; NYSE: BMY) announced receiving another indication approval from the European...
Accropeutics Closes RMB100 Million Series B+ Round to Advance Inflammatory Disease Pipeline
Accropeutics Inc., a clinical-stage biotech company with operations in New York, US, and Suzhou, China,...
Life Molecular Imaging Launches Neuraceq in Hong Kong for Alzheimer’s Detection
Life Molecular Imaging Ltd., a subsidiary of South Africa’s Life Healthcare Group focused on PET...
Frontera Therapeutics Receives NMPA Approval for FT-003 in Diabetic Retinopathy Study
Sino-US firm Frontera Therapeutics, Inc. announced receiving approval from China’s National Medical Products Administration (NMPA)...
Inari Medical Wins NMPA Approval for Thrombectomy Stent System in China
US-based Inari Medical, Inc. (NASDAQ: NARI), set to be acquired by Stryker (NYSE: SYK), announced...
Jiangsu Hengrui Pharmaceuticals’ Tegileridine Approved for Postoperative Pain Management
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving another indication approval from the...
Doma Biopharmaceutical’s HER3-MUC1 Targeted ADC DM002 Receives NMPA Clinical Approval
China-based Doma Biopharmaceutical (Suzhou) Co., Ltd announced receiving clinical approval from the National Medical Products...
MicroPort Endovascular MedTech’s Cratos System Approved for Aortic Dissection Treatment
Shanghai MicroPort Endovascular MedTech Co., Ltd’s (SHA: 688016) Cratos branched aortic stent graft system has...
Akeso Biopharma’s Penpulimab Approved for First-Line NPC Treatment
China-based Akeso Biopharma (HKG: 9926) announced receiving another indication approval from the National Medical Products...